XTL Biopharmaceuticals (NASDAQ: XTLB) names Niv Segal CFO as Weinstein exits

Rhea-AI Filing Summary

XTL Biopharmaceuticals Ltd. reported a leadership change in its finance team. Chief Financial Officer Itay Weinstein will resign effective December 11, 2025, and the company states his resignation is not due to any disagreement with management.

To replace him, the board appointed Niv Segal as Chief Financial Officer. Segal is a CPA with over 12 years of senior financial management experience, including serving as CFO of G.S. Innplay Labs, where he led a $300M acquisition by Playtika, and CFO of Beach Bum, where he managed its $700M acquisition process. He previously served as Group Corporate Controller at Gix Ltd. and began his career at PwC Israel.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of December, 2025

Commission File Number: 001-36000 

XTL Biopharmaceuticals Ltd. 

(Translation of registrant’s name into English)

26 Ben-Gurion St.

Ramat Gan,
5112001, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒         Form 40-F ☐

On December 5, 2025, XTL Biopharmaceuticals Ltd. (the “Company”) announced that effective December 11, 2025, Mr. Itay Weinstein resigned from his position as Chief Financial Officer of the Company. Mr. Weinstein resignation was not a result of any disagreement with the Company or its management.

To fill in the vacancy created by the resignation of Mr. Weinstein, on November 30, 2025, the Board of Directors of the Company approved the appointment of Mr. Niv Segal as the Company’s Chief Financial Officer instead of Mr. Weinstein.

Mr. Segal, CPA, has over 12 years of senior financial management experience, primarily in the high-tech sector. He served as the Chief Financial Officer of G.S. Innplay Labs, where he led the company’s $300M acquisition by Playtika, and as the Chief Financial Officer of Beach Bum, managing its $700M acquisition process. Earlier, Mr. Segal was the Group Corporate Controller at Gix Ltd. (TASE: GIX; NASDAQ: VBIX), overseeing global finance operations, public company reporting, M&A processes, and SOX compliance. Mr. Segal began his career at PwC Israel, auditing public and private companies. Mr. Segal holds an MBA in Accounting, a BA in Economics and Accounting, and is a Certified Public Accountant in Israel.

About XTL Biopharmaceuticals Ltd. (XTL)

XTL is an IP portfolio company. The Company holds 100% of the share capital of The Social Proxy Ltd. (the “Social Proxy”), a web data company and has sublicensed out an IP portfolio surrounding hCDR1 for the treatment of Lupus disease (SLE).

XTL is traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA).

For further information, please contact:

Investor Relations, XTL Biopharmaceuticals Ltd.

Tel: +972 3 611 6666

Email: ir@xtlbio.com

www.xtlbio.com

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	XTL BIOPHARMACEUTICALS LTD.
Date: December 5, 2025	By:	/s/ Noam Band
		Noam Band
		Chief Executive Officer

2

FAQ

What executive change did XTL Biopharmaceuticals (XTLB) disclose?

XTL Biopharmaceuticals announced that Chief Financial Officer Itay Weinstein will resign effective December 11, 2025. The board has appointed Niv Segal as the new Chief Financial Officer.

Did Itay Weinstein resign from XTLB due to a disagreement?

The company states that Mr. Weinstein’s resignation as Chief Financial Officer was not a result of any disagreement with XTL Biopharmaceuticals or its management.

Who is the new CFO of XTL Biopharmaceuticals (XTLB)?

Niv Segal, a Certified Public Accountant with over 12 years of senior financial management experience, has been appointed Chief Financial Officer by the board of directors.

What relevant experience does new XTLB CFO Niv Segal bring?

Niv Segal previously served as CFO of G.S. Innplay Labs, leading its $300M acquisition by Playtika, and as CFO of Beach Bum, managing its $700M acquisition process. He also worked as Group Corporate Controller at Gix Ltd. and began his career at PwC Israel.

What does XTL Biopharmaceuticals (XTLB) do?

XTL is an IP portfolio company. It owns 100% of The Social Proxy Ltd., a web data company, and has sublicensed an IP portfolio around hCDR1 for treatment of Lupus disease (SLE).

On which exchanges is XTL Biopharmaceuticals (XTLB) traded?

XTL Biopharmaceuticals is listed on the Nasdaq Capital Market under the symbol XTLB and on the Tel Aviv Stock Exchange under the symbol XTLB.TA.